Cargando…

Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea

The nonsystemic antibiotic rifaximin is indicated for irritable bowel syndrome with diarrhea (IBS-D) in adults; however, determinants of response remain unclear. The utility of lactulose breath testing (LBT) in predicting response to rifaximin was examined. METHODS: Adults with IBS-D received open-l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rezaie, Ali, Heimanson, Zeev, McCallum, Richard, Pimentel, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6903366/ https://www.ncbi.nlm.nih.gov/pubmed/31688023 http://dx.doi.org/10.14309/ajg.0000000000000444

Ejemplares similares

Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
por: Lembo, Anthony, et al.
Publicado: (2020)

Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome
por: Zhuang, Xiaojun, et al.
Publicado: (2020)

Determination of Rifaximin Treatment Period According to Lactulose Breath Test Values in Nonconstipated Irritable Bowel Syndrome Subjects
por: Bae, Suhyun, et al.
Publicado: (2015)

Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial
por: Cash, Brooks D., et al.
Publicado: (2017)

Association between Symptoms of Irritable Bowel Syndrome and Methane and Hydrogen on Lactulose Breath Test
por: Lee, Kang Nyeong, et al.
Publicado: (2013)

Rifaximin Therapy of Irritable Bowel Syndrome
por: Koo, Hoonmo L., et al.
Publicado: (2012)

Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin
por: DuPont, Herbert L., et al.
Publicado: (2016)

Rifaximin has the potential to prevent complications of cirrhosis
por: Flamm, Steven L., et al.
Publicado: (2018)

Efficacy and safety of lactulose for the treatment of irritable bowel syndrome
por: Chen, Hong-Bin, et al.
Publicado: (2019)

Lactulose/rifaximin: Lack of drug effect: case report
Publicado: (2021)

Profile of rifaximin and its potential in the treatment of irritable bowel syndrome
por: Iorio, Natalya, et al.
Publicado: (2015)

Patients with breath test positive are necessary to be identified from irritable bowel syndrome: a clinical trial based on microbiomics and rifaximin sensitivity
por: Liu, Zuojing, et al.
Publicado: (2022)

Bile Acid and Gut Microbiota in Irritable Bowel Syndrome
por: Min, Yang Won, et al.
Publicado: (2022)

Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity
por: Pimentel, M., et al.
Publicado: (2017)

Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence
por: Hudson, Mark, et al.
Publicado: (2019)

Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors?
por: Reddymasu, Savio C, et al.
Publicado: (2010)

Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin
por: Chang, Christopher
Publicado: (2018)

Development and Validation of a Biomarker for Diarrhea-Predominant Irritable Bowel Syndrome in Human Subjects
por: Pimentel, Mark, et al.
Publicado: (2015)

Serotonin Pathway of Tryptophan Metabolism in Small Intestinal Bacterial Overgrowth—A Pilot Study with Patients Diagnosed with Lactulose Hydrogen Breath Test and Treated with Rifaximin
por: Chojnacki, Cezary, et al.
Publicado: (2021)

Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study
por: Paik, Yong-Han, et al.
Publicado: (2005)

Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy
por: Wang, Zhida, et al.
Publicado: (2018)

Recurrence of Hepatic Encephalopathy after TIPS: Effective Prophylaxis with Combination of Lactulose and Rifaximin
por: Seifert, Leon Louis, et al.
Publicado: (2021)

High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome
por: Jolley, John
Publicado: (2011)

Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome
por: Boltin, Doron, et al.
Publicado: (2014)

Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome
por: Fodor, Anthony A., et al.
Publicado: (2018)

Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis
por: Fu, Jian, et al.
Publicado: (2022)

Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota
por: Wang, Ming-Wei, et al.
Publicado: (2023)

Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials
por: Li, Jun, et al.
Publicado: (2016)

Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus
por: Rezaie, Ali, et al.
Publicado: (2017)

Lactulose Hydrogen Breath Test Result Is Associated with Age and Gender
por: Newberry, Carolyn, et al.
Publicado: (2016)

Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile
por: Gupta, Kamesh, et al.
Publicado: (2017)

Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome
por: Acosta, Andrés, et al.
Publicado: (2016)

Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review
por: Chey, William D., et al.
Publicado: (2020)

Real-World Experience of the One-Year Efficacy of Rifaximin Add-On to Lactulose Is Superior to Lactulose Alone in Patients with Cirrhosis Complicated with Recurrent Hepatic Encephalopathy in Taiwan
por: Chang, Ching, et al.
Publicado: (2021)

Efficacy and Mechanism of Trimebutine Maleate Combined with Lactulose in the Treatment of Constipation-Predominant Irritable Bowel Syndrome in the Elderly
por: Zhou, Yeping, et al.
Publicado: (2022)

Minimal Hepatic Encephalopathy in Indians: Psychometric Hepatic Encephalopathy Score and Inhibitory Control Test for Diagnosis and Rifaximin or Lactulose for Its Reversal
por: Pawar, Vinay B., et al.
Publicado: (2019)

Reduction in Gastrointestinal Cancers in Cirrhotic Patients Receiving Rifaximin vs Lactulose Only Therapy for Hepatic Encephalopathy
por: Patel, Ankoor H, et al.
Publicado: (2023)

Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3
por: Vicari, Enzo, et al.
Publicado: (2014)

Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome
por: Zeber-Lubecka, Natalia, et al.
Publicado: (2016)

Validation of an LC-MS/MS Method for Urinary Lactulose and Mannitol Quantification: Results in Patients with Irritable Bowel Syndrome
por: Gervasoni, Jacopo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0bt9dgroa5kqu7571b6n42qhr7